홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

아이소카르복사지드

Isocarboxazid

HCID 3759
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
59-63-2
표준 SMILES
Cc1cc(C(=O)NNCc2ccccc2)no1
InChIKey
XKFPYPQQHFEXRZ-UHFFFAOYSA-N
분자식
C12H13N3O2
평균 분자량
231.25 g/mol
단동위원소 질량
231.10077667

개요

5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide is a member of benzenes.

이름 및 식별자

우선 이름
Isocarboxazid
IUPAC
N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
현지명
아이소카르복사지드
영어명
ISOCARBOXAZID (200 MG)
분자식
C12H13N3O2
분자량
231.25

이름 및 동의어

isocarboxazid59-63-2IsocarboxazideEnerzerMarplanIsocarbonazidIsocarbossazideN'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazideIsocarboxazidaRo 5-0831Isocarboxazidum5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide
이름 더 보기
이소카복사지드아이소카르복사지드1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazineBmihMarplonBenazideMaraplanro5-0831
3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazideDTXSID4023171NSC-169893RO-5-0831NSC169893DTXCID00317134237V843T4-27-00-03999 (Beilstein Handbook Reference)

데이터베이스 식별자

CAS
59-63-2
PubChem CID
3759
DTXSID
DTXSID4023171
ChEMBL
CHEMBL1201168
ChEBI
CHEBI:93635
UNII
34237V843T
EC Number
200-438-4
Nikkaji
J4.794E

물성

구조 계산 물성

XLogP
1.5
극성 표면적
67.2 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
4
회전 가능 결합 수
4
무거운 원자 수
17
형식 전하
0
복잡도
254

실험 및 물리화학적 성질

Drugs · 2건

DEA NFLIS-Drug Category -> Stimulants

Pharmaceuticals -> Listed in ZINC15

LogP · 2건

2.4

1.49

Solubility · 2건

Very slightly soluble in hot water

2.24e-01 g/L

Human Drugs · 5건

Antidepressants -> Monoamine oxidase inhibitors (MAOI)

Breast Feeding; Lactation; Antidepressive Agents; Monoamine Oxidase Inhibitors;

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Boiling Point394.5ºC at 760 mmHg
Melting Point · 2건

105-106 °C

105 - 106 °C

Physical DescriptionSolid
Dissociation Constants10.4
Collision Cross Section · 2건

150.7 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: Antidepressants]

152.1 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 2 notifications to the ECHA C&L Inventory.

유해성 정보

Regulatory Information3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesAcute Tox. 3 (100%)

독성 정보

Treatment · 1건

General supportive measures should be used, along with immediate gastric lavage or emetics. If the latter are given, the danger of aspiration must be borne in mind. An adequate airway should be maintained, with supplemental oxygen if necessary. The mechanism by which amine-oxidase inhibitors produce hypotension is not fully understood, but there is evidence that these agents block the vascular bed response. Thus it is suggested that plasma may be of value in the management of this hypotension. Administration of pressor amines such as levarterenol bitartrate may be of limited value (note that their effects may be potentiated by Isocarboxazid). Continue treatment for several days until homeostasis is restored. Liver function studies are recommended during the 4 to 6 weeks after recovery, as well as the time of overdosage.

Hepatotoxicity · 1건

Isocarboxazid, like most monoamine oxidase (MAO) inhibitors, can cause transient serum aminotransferase elevations in a proportion of patients. These elevations are usually mild, asymptomatic and self-limited and do not require dose modification. MAO inhibitors have been associated with rare cases of acute, clinically apparent liver injury but isocarboxazid has not specifically been implicated. The time to clinical onset of liver injury due to MAO inhibitors is typically 1 to 4 months after starting and the usual pattern of serum enzyme elevations is hepatocellular, although cholestatic injury has also been described. Immunoallergic features (rash, fever, eosinophilia) are uncommon as is autoantibody formation. Isocarboxazid has not been directly implicated in cases of drug-induced liver injury but it has had limited clinical use.

화학 및 산업

약리 정보

ATC Code · 2건

N - Nervous system

QN - Nervous system

Protein Binding · 1건

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs present a very high protein binding percentage.

Pharmacodynamics · 1건

In vivo and in vitro studies demonstrated isocarboxazid-driven inhibition of MAO in the brain, heart, and liver. The reduced MAO activity, caused by isocarboxazid, results in an increased concentration of serotonin, epinephrine, norepinephrine, and dopamine in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. The increase of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors like isocarboxazid.

Mechanism of Action · 1건

Isocarboxazid works by irreversibly blocking the action of monoamine oxidases (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B). Isocarboxacid, like other monoamine oxidase inhibitors, are unique psychopharmacological agents whose clinical effect is related to the direct action of the monoamine oxidases to transform them into reactive metabolites.

Biological Half-Life · 1건

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. The isocarboxazid half-life is of little interest as it is an irreversible monoamine oxidase inhibitor. These drugs present a very short half-life of 1.5-4 hours due to rapid hepatic metabolism.

Metabolism/Metabolites · 2건

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are rapidly metabolized by acetylation in the liver. As part of the metabolism, hippuric acid is a major metabolite.

관련 반응

0건
반응 기록 만들기
아직 관련 반응이 없습니다

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

물리화학적 성질

녹는점
98 · 98-1000C
끓는 점
373.33 °C · 373.33°C (rough estimate)
밀도
1.206 · 1.206
굴절률
1.529 · 1.5290 (estimate)
저장 조건
-20 °C · -20°C Freezer
용해도
Acetonitrile: Slightly Soluble; Chloroform: Slightly Soluble
물리적 상태
고체
산도 계수 (pKa)
10.4 · pKa 10.4 (Uncertain)
색상
White to off-white
수용성
0.8 g/L · 0.8g/L(25℃)
InChI
1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
InChIKey
XKFPYPQQHFEXRZ-UHFFFAOYSA-N
SMILES
Cc1cc(no1)C(=O)NNCc2ccccc2

화학적 성질

Pale Yellow Solid

Exposure RoutesWell absorbed from the gastrointestinal tract.
Toxicity Summary · 1건

Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase–A (MAO-A) and monoamine oxidase–B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors.

Signs and Symptoms · 1건

Signs of overdose include severe anxiety, confusion, convulsions, cool clammy skin, severe dizziness, severe drowsiness, fast and irregular pulse, fever, hallucinations, severe headache, high or low blood pressure, hyperactive reflexes, muscle stiffness, respiratory depression or failure, slowed reflexes, sweating, severe trouble in sleeping, and unusual irritability.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Isocarboxazid

Ambiguous-DILI-concern

5

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

wgk
WGK 3
ridadr
3249
HS 번호
2934990002
포장분류
III
위험 등급
6.1(b)
Hazard Classifications
Acute Tox. 3 Oral
스토리지 클래스
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

Hepatic and rapid (by oxidation).

FDA Pharmacological Classification · 6건

34237V843T

ISOCARBOXAZID

Established Pharmacologic Class [EPC] - Monoamine Oxidase Inhibitor

Mechanisms of Action [MoA] - Monoamine Oxidase Inhibitors

Isocarboxazid is a Monoamine Oxidase Inhibitor. The mechanism of action of isocarboxazid is as a Monoamine Oxidase Inhibitor.

ISOCARBOXAZID

MeSH Pharmacological Classification · 2건

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)

Absorption, Distribution and Excretion · 2건

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are readily absorbed by the GI tract, present a low bioavailability and reach peak concentrations in 1-2 hours.

Most of the eliminated dose is found in the urine, accounting for the 42.5% of the administered dose after 24 hours. From this amount, 75% of the renally eliminated drug is in the form of hippuric acid. Another section of the eliminated dose is observed through the intestinal tract and it accounts for 22% of the administered dose after 24 hours.

Cellular LocationsCytoplasm

용도 및 제조

UsesMay be used to treat major depressive disorder.
Use ClassificationPharmaceuticals

응용 분야

용도Monoamine oxidase inhibitor. Antidepressant

상·하류 제품 정보

상류 원료

수소화 리튬알미늄벤즈알데하이드5-메틸-이속사졸-3-카르복실산히드라지드Benzylhydrazine dihydrochloride5-메틸-3-이속사졸카르복실산벤질리덴히드라지드메틸5-메틸이속사졸-3-카르복실레이트Benzylhydrazine